Thursday, October 17, 2019

Naturally kills cancer cell: Olive Oil Kills cancer cells

A tumor is an irregular body tissue swelling or enlargement. Tumors can be either benign or malignant. Benign tumors are cancers whose original site cells remain. We form a localized cell mass that encapsulates when it develops and causes death only rarely.

On the other hand, malignant and cancerous tumors invade the tissue in which they develop. They often pass into the lymphatic system and the bloodstream, forming secondary tumors at other sites known as metastases. Growth rate and metastasis vary depending on the tumor type.

Different environmental factors (physical factors: radiation; chemical factors: other nutrient constituents) and genetic factors are involved in tumor formation. Environmental factors are most significant in most types of cancer.

Cancer is one of the main death causes in developed countries, and its incidence is on the rise.
It is now accepted that a relationship exists between diet and a large number of malignant tumors growing. One of the major risks of cancer development is cell oxidation: the more susceptible the cell is to oxidation, the higher the cancer risk.

Colorectal, prostate, and breast cancer are the types of cancer most closely associated with diet. Recent research has shown that the type of fat tends to have more implications for the incidence of cancer than the amount of fat.

OLIVE OIL AND CANCER Olive oil has a protective effect against certain malignant tumors (breast, prostate endometrium, digestive tract).

Several studies have shown that olive oil reduces the risk of breast cancer. Eating a healthy diet of olive oil as the main source of fat could significantly reduce cancer incidence. The theory for this is that cell mutation caused by cancer are partly caused by diet-ingested toxins that damage DNA. The body needs vitamins and antioxidants like those in olive oil to fight such free radicals.
It has also been documented that a diet rich in olive oil is associated with a reduced risk of intestinal cancer. The protective effect of olive oil is independent of the amount of fruit and vegetables eaten in the diet.
Recent studies have shown that olive oil protects against colon cancer. Work has recently been performed on the metabolic effects of fats, in particular, the protective function of olive oil in chronic liver disease and is an intestinal disorder known as Crohn's disease. The findings point to the beneficial effects of olive oil on pre-cancer lesions. Research scientists have come to different conclusions after studying three forms of diet. The olive oil diet reduced the number of cancer lesions; the number of tumors that formed was obviously and substantially small, and the tumors were less aggressive and had a good prognosis.

This beneficial effect maybe linked to oleic acid, the predominant monounsaturated fatty acid in olive oil. It has been found that this fatty acid decreases the production of arachidonic acid-derived prostaglandins, which in turn plays a significant role in the production and development of tumors.
However, it is not excluded that other components of olive oil, such as antioxidants, flavonoids, polyphenols, and squalene, may also have a positive effect. Squalene is thought to have a positive effect on the skin by decreasing the occurrence of melanoma.
Olive oil also contributes to the flavor of vegetables and pulses, the advantages of which have been generally documented in cancer prevention.
Some very interesting, current research focuses on the defense of olive oil against childhood leukemia and various cancers, such as oesophageal squamous cell cancer.
Much remains to be known on how olive oil affects cancer, and there is still a lack of concrete evidence on the mechanisms behind the beneficial role that olive oil plays in preventing or inhibiting the growth of different types of cancer. Nevertheless, according to the data currently available, olive oil could be active at the same time during the different stages involved in the cancer formation cycle.

Immuno therapy for Cancer Treatment ( Y trap )

Johns Hopkins scientists have invented a new class of cancer immunotherapy drugs that are more effective in harnessing the power of the immune system to fight cancer. This new approach, as stated in Nature Communications, results in a significant decrease in tumor growth, even against cancers that do not respond to conventional immunotherapy.

"The immune system is usually capable of detecting and removing the tumor cells. Nevertheless, virtually all cancers— including the most common cancers, from lung, breast, and colon cancers to melanomas and lymphomas — are emerging to combat and overcome such immune surveillance by co-opting and amplifying the natural mechanisms of immune suppression, "says Atul Bedi, M.D., M.B.A., associate professor of otolaryngology-head and neck surgery at the Johns Hopkins University School of Medi.

The major way tumors invade the immune system is through regulatory T cells (Tregs), a subset of immune 
cells that deactivate the immune system's ability to destroy tumor cells. Tumors are often invaded by Tregs and this is strongly correlated with poor outcomes in several types of cancer.

Some tumors produce high levels of a protein that facilitate the production of Tregs. Bedi's team argued that since Tregs in the tumor shuts down immune responses to tumor cells, switching Tregs off may help to make immunotherapy work better.

"This is particularly challenging because Tregs is not only caused by TGFbeta (transforming growth factor-beta) protein formed by tumor cells but also allows TGFbeta to maintain its own identity and function in the tumor," says Bedi. Tregs also produce cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) which prevents anti-tumor immune cells from functioning.

To address this issue, scientists have invented a new class of immunotherapy drugs called Y-traps. Every Y-trap molecule is an antibody shaped like a Y and fused to a molecular "trap" which traps other molecules in the vicinity, making them useless.

The researchers first designed a Y-trap that targets CTLA-4 and traps TGFbeta. This Y-trap disables both CTLA-4 and TGFbeta, which allows anti-tumor immune cells to battle the tumor and disables Treg cells.
The group transplanted human cancer cells into mice designed to have human immune cells to test Y-traps. Researchers found that their Y-trap killed Treg cells in tumors and delayed the growth of tumors that did not respond to ipilimumab, the latest immunotherapy a drug that targets the CTLA-4 protein.

"Tregs have been a thorn in the hand of cancer immunotherapy for a long time," says Bedi. "We finally found a way to conquer this hurdle with this CTLA-4-targeted Y-trap."

Antibodies to another immune checkpoint protein, PD-1 or its ligand (PD-L1), are at the core of modern cancer immunotherapy. Although they work in some patients, they do not work in the vast majority of patients.

The research team developed the Y-trap targeting PD-L1 and the trapping of TGFbeta. Tested against the same engineered mice, they found that their Y-trap works better than PD-L1-targeting drugs atezolizumab and avelumab. Once, this Y-trap delayed the growth of tumors that had not previously reacted to drugs.

"These first-in-class Y-traps are only the start. We have already discovered a whole family of these multifunctional molecules based on the technology of Y-trap. Because immune dysfunction mechanisms are shared across many
types of cancer, this approach could have a large effect on improving cancer immunotherapy, "says Bedi. "Y-traps could also provide a therapeutic strategy against tumors that are resistant to existing immune checkpoint inhibitors."

"This technique appears to be a groundbreaking method and an exciting technical achievement to target multiple tumor microenvironment suppression mechanisms," says Robert Ferris, MD, Ph.D., Professor of Oncology and Director of the Hillman Cancer Center at the University of Pittsburgh. Ferris was not related to the report. "I look forward to seeing its introduction to the hospital." Bedi plans to use Y-traps not only for the treatment of advanced metastatic cancers but also as neoadjuvant therapy to create a "vaccine" effect— that is, to give them to patients before surgery to prevent recurrence of the disease.

Other members of the study are Rajani Ravi, Kimberly Noonan, Vui Pham, Piotr Wysocki, Ranee Mehra, Sridhar Nimmagadda, Luigi Marchionni, David Sidransky, Ivan Borrello and Evgeny Izumchenko of Johns Hopkins University, Alex Zhavoronkov, Ivan Ozerov, Eugene Makarov, Artem Artemov of Insilico Medicine, and Rishi Bedi of Stanford University.

The research was funded by the National Institutes of Health Grants R01 CA184199 and SPORE P50 DE019032 and the Maryland Innovation Initiative Award 
 University and licensed to Y-Trap Inc., a company developing the Y-Trap Technology Platform. Bedi and Ravi, from the Maryland Technology Development Corp. to Atul Bedi and Rajani Ravi. 

COI: Bedi and Ravi are inventors of U.S., European and Japanese patents for antibody ligand traps awarded to Johns Hopkins along with Evgeny Izumchenko, Ivan Borrello and Kimberly Noonan, are the founders and investors of Y-Trap Inc. 

Naturally reduce Bad cholesterol: Naturally, increase Good cholesterol ( 4 Brazilian nuts in a month )

One of the craziest research, I've read all year involved feeding people a single serving of Brazil nuts to see what they would do to the cholesterol levels of healthy volunteers. Researchers gave ten men and women a single meal containing nil, two, four, and eight Brazil nuts, and found that the consumption of just that single serving almost instantly increased cholesterol levels. LDL, the so-called "poor" blood cholesterol level, was significantly lower beginning nine hours after the ingestion of nuts, and by no small amount, almost 20 points per day. Drugs don't work that fast, either. It takes about four days for statins to have a significant effect.

Yet this isn't even the crazy part of it.

The authors returned and assessed their cholesterol five days later, and then 30 days later. Now, keep in mind that they haven't eaten Brazil nuts all this time. I had only one helping of Brazil nuts a month ago, and their cholesterol was still down 30 
days later. It went down and stayed down, having eaten just four nuts, that's nuts!

And no, the research was not financed by the Brazil nut industry.

Ironically, in fact, four nuts seemed to work faster than eight nuts to lower bad cholesterol and raise good cholesterol. Such results suggest that eating just four nuts could be enough to raise the levels of LDL and HDL for up to 30 days, and maybe longer— no more than 30 days.

Now, usually, when a study is published in the medical literature showing some a too-good-to-be-true result like this, you want to wait to see the results repeated before you change your clinical practice before you prescribe something to your patients, particularly when the study is done on only ten people, and especially when the findings are simply just too amazing to believe. But if action is inexpensive, simple, harmless, and healthy— eating four Brazil nuts a month— then, in my view, the burden of proof is kind of reversed. I believe the rational default position is to do so until it has been proved otherwise.

We concluded that a single serving was adequate "without causing liver and kidney toxicity." What they're referring to is the high selenium content of Brazil nuts — so high that four eaten every day can potentially push us up against the tolerable daily selenium limit, but not something we need to worry about if we're just eating four once a month.

Brazil nuts contain healthy fats called polyunsaturated and monounsaturated fatty acids.

According to the American Heart Association (AHA), the use of monounsaturated fats or polyunsaturated fats instead of saturated or trans fats help improve cholesterol levels, which reduces the risk of heart disease and stroke.

Brazil nuts also contain dietary fiber. AHA states that consuming fiber-rich foods increase blood cholesterol levels and decrease the risk of heart disease, stroke, obesity, and type 2 diabetes.

The results of the 2019 study showed that higher consumption of tree nuts decreased the risk of cardiovascular disease and heart attack among people living with diabetes.